Ancilia Biosciences

Ancilia is incredibly proud and honored to be named 1 of just 23 winners from over 1,700 proposals submitted to ARPA-H's Sprint for Women's Health program announced today by the White House and First Lady Jill Biden. We are receiving $3M over 2 years that will enable us to advance our lead candidate to IND filing for our first-in-human clinical trial. This innovative therapy addresses bacterial vaginosis, a common but undertreated disease that is associated with serious conditions such as fertility problems and pelvic inflammatory disease. Our solution is a novel bacterial therapy that is immune to predatory viruses and restores the vaginal microbiome to its naturally healthy state. For more information and for links to related materials, visit https://lnkd.in/eV4idYP4

Ancilia co-founder and CEO Alex Sakatos is presenting on Friday, Oct. 18 at the12th Microbiome & Probiotic R&D & Business Collaboration Forum: USA being held in San Diego. If you are attending, drop by the Urology & Women’s Health session from 2:00pm – 3:30pm PT to say hi and to hear Alex's talk on "Deciphering and targeting the virome." For information contact info@globalengage.co.uk.

See our posting this week announcing the closing of our $4.2M initial financing, which positions us well to continue to advance our programs and prepare for a subsequent round of financing later this year. A special thanks to our investors and advisors, and especially our incredibly talented and committed employees, who are making this important journey possible!

We are thrilled to announce the closing of our $4.2M initial funding round. A special thanks to Safar Partners, who led this round, and our other visionary investors who appreciate the tremendous power of our unique approach. We believe that our proprietary tools leveraging the natural function of CRISPR and demystifying the virome will unlock the potential of beneficial bacterial products addressing a broad range of medical and other applications, We are excited about our progress as we embark on this next stage of our growth. For more information see https://lnkd.in/e9gFSkwZ